Results 141 to 150 of about 1,087 (181)
Is Cenobamate the Breakthrough We Have Been Wishing For?
International Journal of Molecular Sciences, 2021 Close to one-third of patients with epilepsies are refractory to current anti-seizure medications; however, trials with cenobamate suggest effectiveness in such patients with focal onset seizures.
Federico Vigevano +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Drugs, 2020
Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset seizures in adult patients.
openaire +2 more sources
Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset seizures in adult patients.
openaire +2 more sources
Cenobamate for the treatment of focal epilepsy
Drugs of Today, 2020Focal-onset or partial seizures are localized to a specific brain area or areas of the cerebral hemisphere. Cenobamate (CNB, Xcopri, YKP-3089; SK Life Science) is a recent U.S. Food and Drug Administration (FDA)-approved drug for the treatment of focal-onset seizures in the adult population.
openaire +2 more sources
Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy
Epilepsy Research, 2023Cenobamate was approved by the US Food and Drug Administration (FDA) based on studies of adjunctive therapy in patients with focal epilepsy. To support the use of cenobamate monotherapy, this pharmacokinetic (PK)-based simulation analysis evaluated the predicted PK exposure of cenobamate when used as monotherapy versus adjunctive therapy.A population ...
Vijay, Vashi +3 more
openaire +2 more sources
Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug
Neurochemical Research, 2020Central nervous system (CNS) injuries annually afflict approximately 2.7 million people in United States only, inflicting costs of nearly 100 billion US dollars. The gravity of this problem is a consequence of severe and prolonged disability of patients due to a scarce regeneration of CNS, along with the lack of efficient neuroprotective and ...
Michał Wiciński +2 more
openaire +2 more sources
Cenobamate for focal seizures — a game changer?
Nature Reviews Neurology, 2020In the first published efficacy study of cenobamate for treatment-resistant focal seizures, high doses produced high seizure-free rates, suggesting cenobamate can outperform existing options. A risk of serious rash and low tolerability at higher doses means further safety studies and clinical experience are needed to determine its clinical value.
openaire +2 more sources
Cenobamate: A Review in Focal-Onset Seizures
CNS DrugsCenobamate (Ontozry®) is a once-daily oral antiseizure medication (ASM) approved in the EU for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation, in adults with epilepsy that have not been adequately controlled despite previous treatment with ≥ 2 anti-epileptic drugs.
Tina, Nie, Sheridan M, Hoy
openaire +2 more sources
Cenobamate efficacy in specific populations
EpilepsiaAbstractMost people with epilepsy are able to achieve good seizure control with currently available medications. However, despite the development of more than 20 new antiseizure medications (ASMs) over the past 30 years, approximately one third of patients (both pediatric and adult) are treatment‐resistant and at risk of increased morbidity and ...
openaire +2 more sources
Efficacy of cenobamate in tumor‐related epilepsy
Epileptic DisordersAbstract Purpose Cenobamate is approved for treating focal epilepsy and has potential for treating tumor‐related epilepsy (TRE) based on potential anti‐tumor effects, though there is little data on efficacy and safety in this patient population.
Guido Chiriboga +8 more
openaire +2 more sources